協創數據(300857.SZ):擬向相關金融機構申請新增2.85億元授信額度
格隆匯 9 月 30日丨協創數據(300857.SZ)公佈,為滿足公司生產經營和發展的需要,公司在原授信額度基礎上,擬向相關金融機構申請新增2.85億元授信額度。綜合授信品種包括但不限於:流動資金貸款、非流動資金貸款、承兑匯票、開具保函、開具信用證、銀行票據池、票據貼現等綜合授信業務。
上述新增授信額度最終以銀行實際審批的授信額度為準,在新增授信額度不超過人民幣2.85億元的額度內,由董事會授權公司董事長與金融機構籤署各類融資合同及其他相關法律文件。
此次新增的融資授信期限為1年,申請授信主體為公司,不構成對外擔保,不屬於關聯交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.